Mucosis Appoints Thomas Johnston to CEO

Groningen, the Netherlands, Sept 17, 2012 / B3C newswire / – Mucosis B.V., the Dutch clin­i­cal-stage biotech­nol­o­gy com­pa­ny devel­op­ing mucos­al vac­cines, today announced the appoint­ment of Thomas Johnston to the posi­tion of Chief Executive Officer, effec­tive imme­di­ate­ly. Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and suc­ceeds Govert Schouten who is leav­ing the Company to found an inter­net start-up.
“Tom has more than 15 years of lead­er­ship expe­ri­ence in the biotech and oth­er indus­tries and has been an invalu­able mem­ber of our exec­u­tive man­age­ment team,” said John Lambert, Chairman of the Mucosis Board of Directors. “He has played a lead role in the ongo­ing roll­out of our Mimopath plat­form licens­ing ini­tia­tive and the devel­op­ment of our over­all strate­gies for con­tin­ued growth. Given Tom’s sub­stan­tial com­mer­cial expe­ri­ence and famil­iar­i­ty with the Company, we are con­fi­dent he is the right per­son to lead Mucosis as we exe­cute our strat­e­gy and fur­ther advance the devel­op­ment and com­mer­cial­iza­tion of the Mimopath plat­form includ­ing our RSV vac­cine can­di­date.” Mr. Lambert con­tin­ued, “I also would like to thank Govert Schouten for his lead­er­ship these past 4 years dur­ing which he helped trans­form Mucosis from a promis­ing start-up into a clin­i­cal-stage biotech Company with a strong tech­nol­o­gy and prod­uct pipeline. We wish him the very best in his future endeav­ors.”
Mr. Johnston said, “I am hon­ored to be giv­en this oppor­tu­ni­ty to take on the role of CEO of Mucosis dur­ing this excit­ing time in the Company’s his­to­ry. Over the past year, our team has com­plet­ed a clin­i­cal proof of con­cept study in human influen­za for the Mimopath plat­form while also advanc­ing our lead vac­cine pro­gram for the pre­ven­tion of RSV into pre-clin­i­cal stud­ies. These and oth­er recent accom­plish­ments posi­tion us very well in the biotech mar­ket­place and I am con­fi­dent that we will be able to exe­cute on our plan to deliv­er sus­tain­able results and dri­ve long-term val­ue for our share­hold­ers.”
Mr. Johnston joined Mucosis from Novavax Inc, a Nasdaq-list­ed clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny. As Vice President of Strategy there, he devel­oped and exe­cut­ed a region­al part­ner­ship strat­e­gy con­clud­ing deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an exec­u­tive-lev­el strate­gic con­sul­tant in a num­ber of indus­tries includ­ing biotech, and held var­i­ous senior-lev­el posi­tions with a num­ber of world-class orga­ni­za­tions such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.

Leave a Reply

Your email address will not be published. Required fields are marked *